N/A N=309 Prospective ED Headache Cohort Study
Headache
Primary: Number of Participants Who Report Moderate or Severe Pain Within 24 Hours of Emergency Department(ED) Discharge — 53; 6; 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Treatment of Acute Migraine Headache in Children
Migrainous Headache
Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03
Phase 4 N=50 Trial of Comprehensive Migraine Intervention
Migraine
Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale
Phase 3 N=205 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraine
Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants
N/A N=459 A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache
Migraine Disorders · Headache
Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants
Phase 2 N=45 Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children
New Daily Persistent Headache (NDPH)
Primary: Pain Intensity — 5.82; 4.92 score on a scale
N/A N=102 A Randomized Multicentre Study for the Acute Relief of Episodic and Chronic Cluster Headache.
Cluster Headache
Primary: Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment — 495; 400; 67; 46 Number of attacks
Phase 4 N=58 Intravenous Fluids in Benign Headaches Trial
Headache
Primary: Reduction in Pain Scores at 60 Minutes — 48.7; 48.3 reduction in visual analog pain score
Phase 2 N=40 Sumatriptan as Treatment for Post-traumatic Headache
Post-traumatic Headache
Primary: Change in Headache Relief — 23 percentage of headaches resolved — p=.079
N/A N=40 Effect of Intranasal Oxytocin on Headache in Chronic Daily Headache
Chronic Daily Headache
Primary: Reduction in Headache Intensity — 6; 4; 1; 3 Participants
Phase 4 N=123 Metoclopramide Versus Ketorolac for Tension-type Headache
Headache
Primary: Change in Pain Score — 3.8; 5.1 units on a scale
Phase 4 N=5 An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache
Pain
Primary: Change in Pain Score at 60 Minutes — 4; 5 score on a scale
N/A N=18 Clinical Decision Support for Patient Migraine Management
Migraine
Primary: Adherence to Acute Migraine Management Strategies: Treat Early — 0; 2 Participants
Phase 4 N=220 Corticosteroids for Acute Migraine in the Emergency Department
Migraine
Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days
N/A N=193 Cognitive-Behavior Therapy for Posttraumatic Headache
Post-traumatic Headache · PTSD
Primary: Headache-related Disability Scores on the Headache Impact Test 6 (HIT-6) — 66.1; 66.1; 65.2; 61.9 score on a scale — p=<0.001
N/A N=48 RELAXaHEAD for Headache Patients (Phase II)
Migraine · Headache · Multiple Sclerosis
Primary: Number of Patients Enrolled in the Study — 24; 24 Participants
N/A N=45 Do Patients With Chronic Daily Headache Have Continuous Headache or Moments of Headache Relief?
Chronic Daily Headache
Primary: Number of Subjects With Daily Headache Who Have Continuous Headache — 18; 27 participants
N/A N=100 A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Migraine Headache, Episodic
Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days
N/A N=91 Oxygen Therapy for the Treatment of Undifferentiated Headache in the Emergency Department
Headache
Primary: Time to Relief (Min) — 92.2; 83.9; 35.4 Minutes
N/A N=90 pLatelEts And MigRaine iN patEnt foRamen Ovale
Platelet Aggregation, Spontaneous · Migraine With Aura · Patent Foramen Ovale
Primary: Change in Migraine Characteristics — 43; 2; 17 Participants
N/A N=16,789 Chronic Migraine Epidemiology and Outcomes Study
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Phase 4 N=512 Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
Migraine
Primary: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 — -23.38; -31.33 hours/month — p=< 0.001
N/A N=759 IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headache Disorders, Primary · Migraine With Aura · Migraine Without Aura
Primary: Percentage of Patients With Significant Pain Reduction — 90.3 percentage of participants
N/A N=568 Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Migraine · Episodic Migraine · Headache
Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month
Phase 2 N=21 Metoclopramide for Post-Traumatic Headache. A Pilot Study
Post-Traumatic Headache
Primary: Number of Participants With Sustained Headache Relief — 12 Participants
Phase 3 N=191 NINDS CRC Chronic Migraine Treatment Trial
Chronic Migraine
Primary: Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline — 4.4; 4.7 Moderate to severe headache days…
Phase 4 N=401 Comparing Naproxen to Sumatriptan for Emergency Headache Patients
Migraine · Tension-type Headache · Primary Headache Disorder
Primary: Numerical Rating Scale — 4.1; 4.3 units on a scale
Phase 4 N=122 Olanzapine for Acute Headaches
Headache
Primary: Change in Pain Scores Based on Patient Questionnaire — -2.95; -1.79; -4.49; -2.65 units on a scale of 1-10
N/A N=60 Bronx MBCT-Migraine
Migraine
Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027
Phase 3 N=473 Treatment of Multiple Attacks of Acute Migraine (0462-025)
Migraine Headache
Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants